Showing results (1711-1720 of 1,877) with videos related to

Sort By:
Pageof 188
Stem Cell Research|January 24, 2012
Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomesWalter D Funk, Ivan Labat, Janani Sampathkumar, et al.
International Journal of Cancer|March 15, 2025
Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective studySeug Yun Yoon, Sung-Soo Yoon, Deok-Hwan Yang, et al.
Cancer Research and Treatment|June 2, 2026
Randomized Phase II Study of Bortezomib, Lenalidomide, and Dexamethasone (VRD) Versus Lenalidomide and Dexamethasone (RD) in Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM1910)Jun Ho Yi, Sang Eun Yoon, Ji Hyun Lee, et al.
BMC Cancer|November 12, 2019
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphomaSeok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2022
Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or LeiomyosarcomaChang Gon Kim, Nam Suk Sim, Jeong Eun Kim, et al.
Elife|December 29, 2021
Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARAYo Han Lee, Hyun-Jun Jang, Sounkou Kim, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2019
Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic SyndromeSungwoo Park, Dong Won Baek, Sang Kyun Sohn, et al.
Annals of Hematology|August 18, 2016
Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromesYoo Jin Lee, Sung Woo Park, In Hee Lee, et al.
Pharmaceutics|April 28, 2023
Physicochemical, Pre-Clinical, and Biological Evaluation of Viscosity Optimized Sodium Iodide-Incorporated PasteSoo-Jin Chang, Yu-Jin Kim, Huong Thu Vu, et al.
Nature Communications|October 12, 2022
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancerChoong-Kun Lee, Sun Young Rha, Hyo Song Kim, et al.
Pageof 188